VYGR - Voyager Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.85
0.00 (0.00%)
At close: 4:00PM EDT

22.85 0.00 (0.00%)
After hours: 4:59PM EDT

Stock chart is not supported by your current browser
Previous Close22.85
Open22.60
Bid19.93 x 1200
Ask32.00 x 800
Day's Range22.05 - 23.29
52 Week Range7.76 - 25.74
Volume233,007
Avg. Volume519,024
Market Cap841.62M
Beta (3Y Monthly)2.59
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire3 days ago

    Voyager Therapeutics Announces Management Updates

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the retirement of Dinah Sah, Ph.D. as Voyager’s chief scientific officer, and the appointment by Voyager of Omar Khwaja, M.D., Ph.D., currently Voyager’s chief medical officer, to the expanded role of chief medical officer and head of research and development. Dr. Sah has agreed to serve as a consultant to Voyager and become a member of its scientific advisory board.

  • GlobeNewswire17 days ago

    Voyager Therapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today reported its first quarter 2019 financial results, program progress and corporate updates. “The first quarter was an eventful period for Voyager as we announced new collaborations, provided updates to our pipeline programs, and advanced our discovery efforts focused on novel gene therapy capsids that have the potential to cross the blood-brain barrier and target specific cells within the brain after a single, systemic administration,” said Andre Turenne, president and chief executive officer of Voyager.

  • GlobeNewswire19 days ago

    Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson’s Disease at the American Academy of Neurology Annual Meeting

    Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR) today announced Phase I trial results for VY-AADC from eight patients with Parkinson’s disease who participated in the open-label trial to evaluate the safety and efficacy of VY-AADC and to further assess the posterior (i.e., from the back of the head) surgical delivery approach. Treatment with VY-AADC improved good ON time (ON time without troublesome dyskinesia) by 1.7 hours from baseline and reduced OFF time by 2.2 hours at 12 months from baseline in patients with Parkinson’s disease.

  • GlobeNewswire25 days ago

    Voyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) taking place April 29-May 2, 2019, in Washington, D.C. New preclinical data at this year’s ASGCT relate to Voyager’s vectorized antibody program directed against tau for the potential treatment of Alzheimer’s disease, its new TRACER™ system to discover adeno-associated virus (AAV) capsids with blood-brain barrier crossing and cell-specific transduction properties, as well as VY-SOD102 targeting a monogenic form of Amyotrophic Lateral Sclerosis (ALS) called SOD1. “One of the major limitations of biologic therapies for the treatment of severe neurodegenerative diseases is the ability of those therapies to cross the blood-brain barrier,” said Dinah Sah, Ph.D., chief scientific officer of Voyager.

  • GlobeNewswirelast month

    Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting

    CAMBRIDGE, Mass., April 15, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.

  • GlobeNewswire2 months ago

    Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c)(4)

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, granted restricted stock units and a non-qualified stock option to Robert Hesslein as inducements material to his entering an employment agreement with Voyager to serve as its general counsel. The inducement awards were approved by the Compensation Committee of Voyager’s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4) and became effective upon the commencement of Mr. Hesslein’s employment on April 1, 2019. Mr. Hesslein received a restricted stock unit award for 28,125 shares of Voyager common stock and a non-qualified stock option to purchase 168,750 shares of Voyager common stock.

  • GlobeNewswire2 months ago

    Voyager Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

    CAMBRIDGE, Mass., April 02, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.

  • GlobeNewswire2 months ago

    Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology

    Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR) today announced the publication of interim results from the Phase 1b trial of VY-AADC, an investigational gene therapy treatment for Parkinson’s disease, in the peer-reviewed journal, Annals of Neurology. The publication titled “Magnetic Resonance Imaging-Guided Phase 1 Trial of Putaminal AADC Gene Therapy for Parkinson's Disease,” can be accessed online.

  • GlobeNewswire2 months ago

    MRI Interventions Announces Collaboration with Voyager Therapeutics for the Design, Manufacture and Supply of V-TAG™ Device

    MRI Interventions, Inc. (MRIC) a platform neurosurgery company developing products designed to deliver navigation, ablation, deep brain stimulation, aspiration, biopsy and gene therapy today announced a collaboration with Voyager Therapeutics, Inc. (VYGR) to design, manufacture and supply the Variable Trajectory Array Guide, or V-TAG, neurosurgical device for Voyager.  Under the collaboration, Voyager transferred its existing 510(k) clearance for the V-TAG device to MRI Interventions who will manufacture and supply the device as a choice for neurosurgeons, along with MRI’s Clearpoint® system, for use in Voyager’s RESTORE-1 Phase 2 trial of its VY-AADC gene therapy program for Parkinson’s disease. “We continue to evolve and expand our relationship with Voyager with the common goal of delivering gene therapy to specific regions of the brain with accuracy to give our patients the best possible chance at success,” commented Joe Burnett, President and CEO at MRI Interventions.

  • ACCESSWIRE3 months ago

    Rare Disease Therapies Draw Big Biopharma's Interest

    HENDERSON, NV / ACCESSWIRE / March 8, 2019 / The past few weeks have been busy with big bio taking over smaller biotechs developing novel therapies. Roche (RHHBY) said it would spend $4.8 billion in a ...

  • GlobeNewswire3 months ago

    Consolidated Research: 2019 Summary Expectations for AMC Entertainment, Spirit Airlines, Voyager Therapeutics, CIT Group, Kaman, and CommVault — Fundamental Analysis, Key Performance Indications

    NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire3 months ago

    Voyager Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights

    Initiated RESTORE-1 Phase 2 trial for VY-AADC for Parkinson’s disease Began IND-enabling preclinical studies for ALS-SOD1 and Huntington’s disease programs Recently announced.

  • ACCESSWIRE3 months ago

    Watch These Four Biotech Stocks Friday

    CORAL GABLES, FL/ ACCESSWIRE / February 22, 2019 / With the new year only a few months old, the biotech stock market is already whirring with the excitement surrounding companies developing nuanced approaches to creating a wide array of new forms of treatment options for patients in need of care. Naturally, companies in the biotech sector working to address these challenges are garnering significant notoriety among consumers as well as investors. Premier Health Group (PHGRF) (PHGI), Ocular Therapeutix Inc (OCUL), Voyager Therapeutics Inc (VYGR), and Amarin Corporation plc (NASDAQ:AMRN) represent 4 biotech stocks stepping up their game on Friday.

  • GlobeNewswire3 months ago

    Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies

    The delivery of sufficient quantities of antibodies across the blood-brain barrier is one of the major limitations of current biologic therapies for neurodegenerative diseases that require frequent systemic injections with large amounts of antibodies. Voyager’s vectorized antibody platform and approach aims to circumvent this limitation by delivering, with a potential one-time intravenous administration, the genes that encode for the production of therapeutic antibodies utilizing Voyager’s blood-brain barrier penetrant adeno-associated virus (AAV) capsids.

  • PR Newswire3 months ago

    AbbVie and Voyager Therapeutics Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies

    - Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein - Voyager to receive $65 million upfront and up to $245 million in preclinical and Phase ...

  • GlobeNewswire3 months ago

    Voyager Therapeutics to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., Feb. 19, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.

  • GlobeNewswire3 months ago

    Voyager Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call

    CAMBRIDGE, Mass., Feb. 18, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.

  • Business Wire3 months ago

    Voyager Launches Highly Anticipated Retail Mobile App for Commission-Free Crypto Asset Trading

    JERSEY CITY, N.J.-- -- Smart order routing technology connects to multiple exchanges and liquidity providers for access to more liquidity and better trade execution End-to-end solution enables trading with crypto wallet and custody solutions Advanced analytics, alerts, news feeds to research investments, monitor positions Instant funding and trading of 18 crypto assets with zero-commissions Voyager ...

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The ...

  • GlobeNewswire4 months ago

    Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia

    Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases Neurocrine.

  • GlobeNewswire4 months ago

    Consolidated Research: 2019 Summary Expectations for Southern, Exelon, PriceSmart, Five Prime Therapeutics, Digi International, and Voyager Therapeutics — Fundamental Analysis, Key Performance Indications

    NEW YORK, Jan. 16, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire4 months ago

    Voyager Therapeutics to Appoint Omar Khwaja, M.D., Ph.D., as Chief Medical Officer

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the appointment of Omar Khwaja, M.D., Ph.D., as chief medical officer. Dr. Khwaja’s background includes extensive research, translational, and clinical therapeutic development experience in neuroscience, neurogenetics and rare disease in both industry and academic roles. Dr. Khwaja is joining Voyager from F. Hoffmann-La Roche AG (Roche) where he most recently served as Global Head of Neuroscience Translational Medicine and Global Head of Rare Diseases.

  • GlobeNewswire5 months ago

    Voyager Therapeutics Provides Updates for VY-AADC Clinical Program for Parkinson’s Disease

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced an update to its VY-AADC clinical program for Parkinson’s disease. In December 2018, the Company held a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss the overall development program for VY-AADC.

  • GlobeNewswire5 months ago

    Voyager Therapeutics Joins Michael J. Fox Foundation Initiatives and Education Campaigns to Accelerate the Development of New therapies and a Cure for Parkinson’s Disease

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced joining multiple partnerships with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) including the Parkinson’s Progression Markers Initiative (PPMI) and the Parkinson’s Disease Education Consortium (PDEC). “We are dedicated to finding a cure for Parkinson's disease and accelerating breakthroughs patients can feel in their everyday lives,” said Sohini Chowdhury, deputy chief executive officer of The Michael J. Fox Foundation.

  • GlobeNewswire5 months ago

    Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson’s Disease

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced dosing of the first patient in RESTORE-1, a Phase 2, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of VY-AADC for the treatment of Parkinson’s disease in patients with motor fluctuations that are refractory to medical management. “Patients with Parkinson’s disease need new therapeutic options, especially as the disease progresses and there is less AADC enzyme in parts of the brain where it is needed to convert levodopa to dopamine,” said Mark Richardson, M.D., Ph.D., Associate Professor, Director of Epilepsy and Movement Disorders Surgery at the University of Pittsburgh Medical Center and principal investigator in the RESTORE-1 trial.